Journal article
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
- Abstract:
-
Background Sodium–glucose co-transporter-2 (SGLT2) inhibitors reduce progression of chronic kidney disease and the risk of cardiovascular morbidity and mortality in a wide range of patients. However, their effects on kidney disease progression in some patients with chronic kidney disease are unclear because few clinical kidney outcomes occurred among such patients in the completed trials. In particular, some guidelines stratify their level of recommendation about who shoul...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 668.4KB, Terms of use)
-
- Publisher copy:
- 10.1016/S2213-8587(23)00321-2
Authors
- Publisher:
- Elsevier
- Journal:
- Lancet Diabetes and Endocrinology More from this journal
- Volume:
- 12
- Issue:
- 1
- Pages:
- 39-50
- Publication date:
- 2023-12-04
- Acceptance date:
- 2023-10-25
- DOI:
- EISSN:
-
2213-8595
- ISSN:
-
2213-8587
- Language:
-
English
- Keywords:
- Pubs id:
-
1552533
- Local pid:
-
pubs:1552533
- Deposit date:
-
2023-10-25
Terms of use
- Copyright holder:
- EMPA-KIDNEY Collaborative Group
- Copyright date:
- 2023
- Rights statement:
- Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
- Notes:
- For the purpose of open access, the authors have applied a Creative Commons Attribution (CC BY) licence to any Author Accepted manuscript version arising.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record